475 related articles for article (PubMed ID: 29627951)
21. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
[TBL] [Abstract][Full Text] [Related]
22. Secular trends in the epidemiology of Clostridium difficile infection (CDI) at a tertiary care hospital in Barcelona, 2006-2015: A prospective observational study.
Larrainzar-Coghen T; Rodríguez-Pardo D; Fernández-Hidalgo N; Puig-Asensio M; Pigrau C; Ferrer C; Rodríguez V; Bartolomé R; Campany D; Almirante B
Anaerobe; 2018 Jun; 51():54-60. PubMed ID: 29655966
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.
Carignan A; Poulin S; Martin P; Labbé AC; Valiquette L; Al-Bachari H; Montpetit LP; Pépin J
Am J Gastroenterol; 2016 Dec; 111(12):1834-1840. PubMed ID: 27619835
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China.
Cui Y; Dong D; Zhang L; Wang D; Jiang C; Ni Q; Wang C; Mao E; Peng Y
BMC Infect Dis; 2019 Nov; 19(1):961. PubMed ID: 31711425
[TBL] [Abstract][Full Text] [Related]
25. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.
Jardin CG; Palmer HR; Shah DN; Le F; Beyda ND; Jiang Z; Garey KW
J Hosp Infect; 2013 Sep; 85(1):28-32. PubMed ID: 23834988
[TBL] [Abstract][Full Text] [Related]
26. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
[TBL] [Abstract][Full Text] [Related]
27. Community-acquired Clostridium difficile infection in Serbian pediatric population.
Predrag S; Branislava K; Nikola S; Niko R; Zorica SR; Stanković-Đorđević D
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1061-1069. PubMed ID: 29497879
[TBL] [Abstract][Full Text] [Related]
28. Clostridium difficile infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in a non-epidemic setting.
Scardina T; Labuszewski L; Pacheco SM; Adams W; Schreckenberger P; Johnson S
Infect Control Hosp Epidemiol; 2015 Mar; 36(3):280-6. PubMed ID: 25695169
[TBL] [Abstract][Full Text] [Related]
29. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
30. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
Parmar SR; Bhatt V; Yang J; Zhang Q; Schuster M
J Oncol Pharm Pract; 2014 Jun; 20(3):172-82. PubMed ID: 23804627
[TBL] [Abstract][Full Text] [Related]
31. Recurrent
Song JH; Kim YS
Gut Liver; 2019 Jan; 13(1):16-24. PubMed ID: 30400734
[TBL] [Abstract][Full Text] [Related]
32. Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China.
Huang H; Wu S; Chen R; Xu S; Fang H; Weintraub A; Nord CE
Anaerobe; 2014 Dec; 30():65-9. PubMed ID: 25219941
[TBL] [Abstract][Full Text] [Related]
33. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older.
Cober ED; Malani PN
J Am Geriatr Soc; 2009 Apr; 57(4):659-62. PubMed ID: 19392957
[TBL] [Abstract][Full Text] [Related]
34. Impact of Clostridium difficile recurrence on hospital readmissions.
Olsen MA; Yan Y; Reske KA; Zilberberg M; Dubberke ER
Am J Infect Control; 2015 Apr; 43(4):318-22. PubMed ID: 25690876
[TBL] [Abstract][Full Text] [Related]
35. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
36. Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres.
Pakyz AL; Jawahar R; Wang Q; Harpe SE
J Antimicrob Chemother; 2014 Apr; 69(4):1127-31. PubMed ID: 24327619
[TBL] [Abstract][Full Text] [Related]
37. [Individualized treatment strategies for Clostridium difficile infections].
Solbach P; Dersch P; Bachmann O
Internist (Berl); 2017 Jul; 58(7):675-681. PubMed ID: 28589214
[TBL] [Abstract][Full Text] [Related]
38. Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country.
Lo Vecchio A; Lancella L; Tagliabue C; De Giacomo C; Garazzino S; Mainetti M; Cursi L; Borali E; De Vita MV; Boccuzzi E; Castellazzi L; Esposito S; Guarino A
Eur J Clin Microbiol Infect Dis; 2017 Jan; 36(1):177-185. PubMed ID: 27696233
[TBL] [Abstract][Full Text] [Related]
39. Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?
Robin C; Héquette-Ruz R; Guery B; Boyle E; Herbaux C; Galperine T
Med Mal Infect; 2017 Dec; 47(8):532-539. PubMed ID: 28823390
[TBL] [Abstract][Full Text] [Related]
40. Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density.
Kimura T; Stanhope S; Sugitani T
J Infect Chemother; 2020 May; 26(5):438-443. PubMed ID: 32081648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
